

NCT Number	Sponsor Protocol Number	Generic Name	Study Phase	Study Title	Study Synopsis	Protocol with Admendments Availale
NCT00299715	R076477-BIM-3001	paliperidone	3	Efficacy and Safety of OROS vs. Placebo in the treatment of Manic Episodes Assoc. w/ Bipolar Disorder	No	No
NCT00309699	R076477-BIM-3002	paliperidone	3	Efficacy & Safety of PALI v. Placebo or Comparator in the Treatment of Manic Episodes Assoc. w/Bipolar I Disorder	No	No
NCT00309686	R076477-BIM-3003	paliperidone	3	Randomized, DB, PC, STUDY TO EXPLORE EFFICACY & SAFETY OF ADDING PALI OROS TO MOOD STABILIZER TREATMENT IN BIPOLAR 1	YES	No
NCT00397033	R076477-SCA-3001	paliperidone	3	Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.	YES	YES
NCT00412373	R076477-SCA-3002	paliperidone	3	Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.	YES	YES
NCT00086320	R076477-SCH-301	paliperidone	3	A double-blind, randomized, parallel arm comparison of extended release OROS paliperidone and placebo in the prevention of recurrence in subjects with schizophrenia.	No	No
NCT00085748	R076477-SCH-302	paliperidone	3	A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Paliperidone Extended Release in the Treatment of Geriatric Patients With Schizophrenia	YES	YES
NCT00650793	R076477-SCH-303	paliperidone	3	A randomized, double- blind, placebo and active controlled parallel group, dose- response study to evaluate the efficacy and safety of 3 fixed dosages of extended release OROS Paliperidone (6, 9 and 12mg/d)and olanzapine(10mg) with OL ext	YES	YES
NCT00077714	R076477-SCH-304	paliperidone	3	A Randomized Double Blind Placebo Controlled Parallel Arm Comparison of Fixed Doses of OROS® Paliperidone in the Treatment of Subjects with Schizophrenia	No	No
NCT00083668	R076477-SCH-305	paliperidone	3	DB, PL, Dose-Response Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended Release OROS® Paliperidone (3, 9, and 15 mg) and Olanzapine (10 mg) in the Treatment of Subjects with Schizophrenia	No	No
NCT00334126	R076477-SCH-3015	paliperidone	3	A randomized, double-blind prospective drug trial to evaluate the efficacy and tolerability of paliperidone as compared with quetiapine and placebo in hospitalized adults with an acute exacerbation of schizophrenia	YES	YES

